Introduction Since their introduction, drug-eluting stents (DES) have revolutionized percutaneous treatment of coronary artery disease with rates of in-stent restenosis of between 2 and 10% [] and ...

Elixir Medical Corp. reported positive 12-month data from the Infinity-Swedeheart trial that compared its Dynamx coronary bioadaptor system to Medtronic plc’s Resolute Onyx zotarolimus drug-eluting ...

Elutia (Nasdaq:ELUT) announced the first-ever patient implant of its EluPro drug-eluting biologic envelope cleared by the FDA ...

A study has found that sirolimus-coated balloons vs thin drug-eluting stents in in-stent restenosis show similar favorable clinical outcomes.

Drug-coated balloon (DCB) angioplasty as the initial strategy for de novo coronary artery stenoses didn't measure up to ...

did not outshine standard treatment with second generation drug-eluting stents (DES) as they were expected to, in a surprise ...

Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced a landmark achievement ...

In recent years, some stents have medications embedded in them designed to further prevent blockage after placement. These drug-eluting stents yield a marked reduction in early reblockage compared ...

bioabsorbable stents, and drug-eluting stents. These stents can be further divided into balloon-expandable and self-expanding types, depending on the deployment mechanism. Report coverage ...

As of 2023, drug-eluting stents hold the largest market share due to their clinical benefits, including a lower incidence of restenosis. These stents are coated with medication that helps prevent ...

Over the past decade, drug-eluting stents (DES) have greatly transformed the field of interventional cardiology. Generally, three components are included in a DES system: a metal stent platform ...